SECTOR OF CARE VARIATIONS IN PRESCRIPTIONS OF SGLT2 INHIBITORS (SGLT2I) AND GLP-1 RECEPTOR AGONISTS (GLP-1 RA) IN THE US MILITARY HEALTH SYSTEM (MHS)

被引：0
|
作者：
Nguyen, Julia [1 ]
Nee, Robert [1 ,2 ]
Marneweck, Hava [3 ]
Banaag, Amanda [3 ]
Koehlmoos, Tracey [2 ]
Oliver, James [1 ,2 ]
机构：
[1] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20814 USA
[2] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA
[3] Henry M Jackson Fdn Advacement Mil Med Inc, Bethesda, MD 20817 USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2025年 / 85卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
G-371
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
    Goncalves, Edison
    Bell, David S. H.
    DIABETES THERAPY, 2018, 9 (03) : 919 - 926
  • [42] Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond
    Olanrewaju, Olusegun A.
    Sheeba, Fnu
    Kumar, Avinash
    Ahmad, Saad
    Blank, Narendar
    Kumari, Reema
    Kumari, Komal
    Salame, Tamara
    Khalid, Ayesha
    Yousef, Nazdar
    Varrassi, Giustino
    Khatri, Mahima
    Kumar, Satish
    Mohamad, Tamam
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [43] GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last? (vol 4, pg 963, 2016)
    Nauck, M. A.
    Meier, J. J.
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (12): : E8 - E8
  • [44] Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
    Scheen, Andre J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 143 : 88 - 100
  • [45] Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Pedro Cardoso
    Katie G. Young
    Anand T. N. Nair
    Rhian Hopkins
    Andrew P. McGovern
    Eram Haider
    Piyumanga Karunaratne
    Louise Donnelly
    Bilal A. Mateen
    Naveed Sattar
    Rury R. Holman
    Jack Bowden
    Andrew T. Hattersley
    Ewan R. Pearson
    Angus G. Jones
    Beverley M. Shields
    Trevelyan J. McKinley
    John M. Dennis
    Diabetologia, 2024, 67 : 822 - 836
  • [46] Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
    Winiarska, Agata
    Knysak, Monika
    Nabrdalik, Katarzyna
    Gumprecht, Janusz
    Stompor, Tomasz
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [47] Protective Effect of GLP-1 Receptor Agonists (GLP-1 RA) and SGLT2 Inhibitors (SGLT2i) against Adverse Cardiovascular (CV) Events in HIV and Type 2 Diabetes Mellitus (T2DM) When Compared with Metformin Alone: A National Database Study
    Alaber, Omar A.
    Chandar, Apoorva K.
    Dahash, Basma A.
    Zuzek, Aleona C.
    Rajpal, Aman
    DIABETES, 2020, 69
  • [48] Global Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: Results from DISCOVER
    Arnold, Suzanne V.
    Tang, Fengming
    Cooper, Andrew
    Chen, Hungta
    Gomes, Marilia B.
    Rathmann, Wolfgang
    Shimomura, Iichiro
    Vora, Jiten
    Watada, Hirotaka
    Khunti, Kamlesh
    Kosiborod, Mikhail N.
    DIABETES, 2021, 70
  • [49] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina M.
    Marsolo, Keith
    Bosworth, Hayden B.
    Pagidipati, Neha
    DIABETES, 2024, 73
  • [50] Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
    Edison Goncalves
    David S. H. Bell
    Diabetes Therapy, 2018, 9 : 919 - 926
12345